Rituximab

利妥昔单抗

Report date: 2026/05/06 20:02:28

Base Information

Drug NameRituximab
Drug Alias NameRituximabumRituximab-EURistova美罗华MabThera +[12] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4] 
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsRejection of pancreatic transplantationRejection of renal transplantationAcquired thrombotic thrombocytopenic purpura +[123] 
Global Approved IndicationsArthritis, RheumatoidLymphoma, Mantle-CellLymphoma, Follicular +[6] 
Approved Indications in ChinaLymphoma, Non-Hodgkin
Original Approved Country/TerritoryUnited States
Original Approved Date1997/11/26
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[61] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBiogen Inc
China Registration ClassN/A

Develop Information

Active CompaniesZenyaku Kogyo Co LtdRoche Pharma AgAmsterdam University Medical Centers +[29] 
Inactive CompaniesShenzhen Hank Bioengineering InstituteDana-Farber Cancer InstituteCarelon Research +[66] 
Active IndicationsRejection of pancreatic transplantationRejection of renal transplantationAcquired thrombotic thrombocytopenic purpura +[47] 
Inactive IndicationsGraft RejectionCNS Embryonal TumorMental Disorders +[76] 

Other Information

ATC CodeL01XC02
Related LinksWikipediaDrugBankKEGG